Dabigatran-13C-d3 is intended for use as an internal standard for the quantification of dabigatran by GC- or LC-MS. Dabigatran is an inhibitor of thrombin (Ki = 0.0045 µM) and an active metabolite of the thrombin inhibitor prodrug dabigatran etexilate .1,2 It also inhibits trypsin (Ki = 0.0503 µM) but is selective for thrombin and trypsin over plasmin, Factor Xa, activated protein C, and tissue plasminogen activator (tPA; Kis = 1.695, 3.76, 20.93, and 45.36 µM, respectively).1
1.Hauel, N.H., Nar, H., Priepke, H., et al.Structure-based design of novel potent nonpeptide thrombin inhibitorsJ. Med. Chem.45(9)1757-1766(2002) 2.Eisert, W.G., Hauel, N., Stangier, J., et al.Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombinArterioscler. Thromb. Vasc. Biol.30(10)1885-1889(2010)